captopril has been researched along with metallothionein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Ismaeel, H; Al-Rikabi, AC; Al-Shabanah, OA; Mansour, MA | 1 |
| Ackerman, Z; Grozovski, M; Oron-Herman, M; Sela, BA; Skarzinski, G | 1 |
2 other study(ies) available for captopril and metallothionein
| Article | Year |
|---|---|
Comparison of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockade for the prevention of premalignant changes in the liver.
Topics: alpha-Fetoproteins; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticarcinogenic Agents; Captopril; Carcinoembryonic Antigen; Endostatins; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factors; Hydroxyproline; Liver; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Metallothionein; Perindopril; Precancerous Conditions; Rats; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2011 |
Effects of antihypertensive and triglyceride-lowering agents on hepatic copper concentrations in rats with fatty liver disease.
Topics: Animals; Antihypertensive Agents; Bezafibrate; Captopril; Copper; Disease Models, Animal; Fatty Liver; Hypolipidemic Agents; Liver; Male; Metallothionein; Rats, Sprague-Dawley; Superoxide Dismutase | 2014 |